Brief: Intelligent Bio Solutions Receives Guidance From U.S. FDA On A Regulatory Pathway For U.S. Expansion Of Its Intelligent Fingerprinting Drug Screening Cartridge
28/06/2023 14:05
June 28 (Reuters) - Intelligent Bio Solutions Inc
INBS.O :
* INTELLIGENT BIO SOLUTIONS RECEIVES GUIDANCE FROM U.S. FDA
ON A
REGULATORY PATHWAY FOR EXPANSION INTO THE UNITED STATES FOR ITS
INTELLIGENT FINGERPRINTING DRUG SCREENING CARTRIDGE
* INTELLIGENT BIO SOLUTIONS: FDA PROVISIONALLY DETERMINED
THAT THE
CARTRIDGE FALLS WITHIN 21 CFR 862.3650, OPIATE TEST SYSTEM, A
CLASS II TYPE DEVICE
Source text for Eikon: ID:nGNX9Typd8
Further company coverage: INBS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intelligent Bio Solutions
See all newsBrief: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth Of 38% Year-Over-Year, Driven By Reader Installed Base And High-Margin Cartridge Growth
Brief: Intelligent Bio Solutions Initiates Clinical Study Supporting FDA Clearance And Planned US Market Entry
Intelligent Bio Solutions Q3 revenue rises 46%, gross margin tops 50%
Intelligent Bio Solutions rise after clearing security tests ahead of FDA filing
Brief: Intelligent Bio Solutions Completes Clinical Cut-Off Study